SCHEMBL3583320

SCHEMBL3583320

CNc1ccc(Cl)cc1C(=O)N(CCc1cccc(OC(F)(F)F)c1)Cc1ccc(C2CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.41
LPAR1 Q92633 1/20 0.39
LPAR5 Q9H1C0 1/20 0.39
DHODH Q02127 1/20 0.39
STAT3 P40763 2/20 0.38
SCN9A Q15858 1/20 0.38
EPHX2 P34913 1/20 0.37
P2RX1 P51575 1/20 0.37
KDM5A P29375 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
SLC6A9 P48067 3/20 0.36
KCNH2 Q12809 2/20 0.36
TRPV1 Q8NER1 1/20 0.36
ATM Q13315 1/20 0.36
SLC2A1 P11166 1/20 0.36
C5AR1 P21730 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3583070 0.97 SCN9A (0.40) CNR1LPAR1LPAR5DHODHSTAT3
SCHEMBL3574302 0.92 CNR1 (0.42) CNR1LPAR1LPAR5DHODHSTAT3
SCHEMBL3575607 0.92 CNR1 (0.40) CNR1LPAR1LPAR5DHODHSTAT3
SCHEMBL3576631 0.92 CNR1 (0.38) CNR1LPAR1LPAR5DHODHSTAT3
SCHEMBL3574145 0.89 SCN9A (0.39) CNR1LPAR1LPAR5DHODHSTAT3
SCHEMBL3575613 0.89 SCN9A (0.39) CNR1LPAR1LPAR5DHODHSTAT3
SCHEMBL3576382 0.89 STAT3 (0.38) CNR1LPAR1LPAR5DHODHSTAT3
SCHEMBL3577812 0.88 LPAR1 (0.43) CNR1LPAR1LPAR5P2RX1KDM5A
SCHEMBL3576340 0.88 CNR1 (0.42) CNR1LPAR1LPAR5SCN9AP2RX1
SCHEMBL3576623 0.88 LMNA (0.41) CNR1TRPV1ATMSLC2A1C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC CNR1 76/4885LPAR1 3429/4885LPAR5 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.